Karyopharm Therapeutics Inc.
Tremor tracks 8 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 6 insiders sold shares within a monthSince May 14, 2026+1.3
Trials
- KPTIKaryopharm Therapeutics Inc11Calm
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
FinishedPhase 1/2277 patientsMain results: Aug 31, 2024 - KPTIKaryopharm Therapeutics Inc1Calm
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Running, no new patientsPhase 3353 patientsMain results: Feb 20, 2026 - KPTIKaryopharm Therapeutics Inc1Calm
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Running, no new patientsPhase 3257 patientsMain results: May 22, 2026 - KPTIKaryopharm Therapeutics Inc1Calm
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Signing up patientsPhase 2127 patientsMain results: Jan 2028 - KPTIKaryopharm Therapeutics Inc1Calm
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
FinishedPhase 1/280 patientsMain results: Jul 31, 2024 - KPTIKaryopharm Therapeutics Inc1Calm
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Running, no new patientsPhase 2/3501 patientsMain results: Dec 2026 - KPTIKaryopharm Therapeutics Inc1Calm
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Running, no new patientsPhase 2244 patientsMain results: Dec 2026 - KPTIKaryopharm Therapeutics Inc1Calm
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Signing up patientsPhase 1/2300 patientsMain results: Apr 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
10 sales (10 not pre-planned) · 0 purchases
- Abate KristinChief Accounting Officer · Oct 16, 2026Sold 4,788 sharesabout $2 thousand · not pre-planned
- Abate KristinChief Accounting Officer · Oct 1, 2026Sold 378 sharesabout $450 · not pre-planned
- Abate KristinChief Accounting Officer · Sep 1, 2026Sold 19 sharesabout $38 · not pre-planned
- Poulton StuartEVP, Chief Development Officer · Jul 28, 2026Sold 189 sharesabout $1 thousand · not pre-planned
- Poulton StuartEVP, Chief Development Officer · May 14, 2026Sold 403 sharesabout $4 thousand · not pre-planned
- Rangwala ReshmaEVP & Chief Medical Officer · May 14, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Warning about being removed from the stock exchangeNews report (8-K)Nov 5, 2026
- Signed a major agreement; Shared information with investors; Other newsNews report (8-K)Nov 3, 2026
- Shared information with investorsNews report (8-K)Nov 2, 2026
- Other newsNews report (8-K)Oct 22, 2026
- Other newsNews report (8-K)Oct 14, 2026